NSE · KREBSBIO · Healthcare
Krebs Biochemicals & Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹44 Cr with net profit ₹-27 Cr — a -61.2% net margin, versus -38.78% the period before.
Shareholding
As of 2026-06-30
- Promoter72.74%
- Public26.76%
- FII0.5%
8,521 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.15× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #4 of 15 by market cap · medians across 4 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Procter & Gamble Health Limited | ₹10,981 Cr | 116.08 | 20.94 | 62.32% | 23.22% |
| Medico Remedies Limited | ₹384 Cr | 65.15 | 5.06 | 17.38% | 6.36% |
| Par Drugs & Chemicals Ltd. | ₹118 Cr | 138.9 | 1.05 | 11.71% | 12.65% |
| Krebs Biochemicals & Industries Ltd.(this company) | ₹117 Cr | — | — | 10.4% | -71.34% |
| Ortin Global Limited | ₹12 Cr | — | 9.95 | -59.85% | -822.22% |
AI analysis
AI-generated · google/gemini-2.5-flashKrebs Biochemicals & Industries Ltd. (symbol: 524518) operates in the Healthcare sector with a market capitalization of Rs 115 Cr. The company is involved in manufacturing and selling active pharmaceutical ingredients, developing biotech processes for medicine, agriculture, and industry, and offering contract manufacturing services. Its product portfolio includes androstenedione, lovastatin, and simvastatin, as well as various products for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. The company reported annual revenue of Rs 44.0208 Cr in March 2025 and a profit margin of -71.34%.
Positives
- +Promoter holding of 72.7445% as of June 30, 2026, indicates significant insider confidence.
- +Debt-to-equity ratio is 0, suggesting no debt on the balance sheet.
- +No promoter shares are pledged, indicating absence of encumbrances on promoter holdings.
Negatives
- −The company has reported a negative profit margin of -71.34%.
- −Net profit has been consistently negative, with a loss of Rs -26.9393 Cr in March 2025.
- −Book value per share is negative at -75.49.
- −Earnings per share (EPS) were -12.49 in March 2025.
- −Return on Capital Employed (ROCE) is negative at -9.0598%.
Business
Krebs Biochemicals & Industries Ltd. manufactures and sells active pharmaceutical ingredients and develops biotech processes. Key products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. Additionally, the company develops products like amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for various medical applications. It also provides contract manufacturing services to pharmaceutical and multinational companies.
Financial Performance
The company's revenue has shown a declining trend in recent years, falling from Rs 54.3217 Cr in March 2021 to Rs 44.0208 Cr in March 2025. Net profit has been consistently negative, with a net loss of Rs -26.9393 Cr reported in March 2025. Quarterly revenue also decreased from Rs 11.47 Cr in December 2024 to Rs 6.81 Cr in March 2026.
Profitability & Returns
Krebs Biochemicals & Industries Ltd. has faced significant profitability challenges. The company reported a negative profit margin of -71.34%. Earnings per share (EPS) have consistently been negative, reaching -12.49 in March 2025. Return on Capital Employed (ROCE) is -9.0598%, indicating inefficient use of capital, and Return on Equity (ROE) is 10.4%.
Balance Sheet
The company's book value is negative at -75.49, suggesting that its liabilities exceed its assets. The debt-to-equity ratio is 0, indicating no outstanding debt reported. However, the negative book value points to a distressed financial position despite the absence of debt.
Ownership & Pledges
As of June 30, 2026, promoters held 72.7445% of the shares. Public shareholding was 26.76%, while Foreign Institutional Investors (FIIs) held 0.4955%. There were no promoter shares reported as pledged.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Krebs Biochemicals & Industries Ltd.share price & fundamentals